HP and pyruvate kinase deficiency of red cells: Patients receiving mitapivat also demonstrated greater improvements in markers of hemolysis (indirect bilirubin, lactose dehydrogenase, and haptoglobin levels) than those receiving placebo, and experienced significant improvements compared with placebo in 2 PK deficiency–specific patient-reported outcomes that assessed the signs, symptoms, and impact of PK deficiency.25